Drug intelligence / Profile preview

mycobiotic

Development stage: Unknown
Lead developer: BioticFoods
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

**Mycobiotic** is a dietary probiotic supplement composed of live strains of lactic acid bacteria, specifically *Lactobacillus plantarum* AMT4, *Lactobacillus plantarum* AMT14, and *Bifidobacterium animalis* AMT30. It is formulated to enrich the gut microbiome, support the limitation of pathogenic bacterial and fungal growth—particularly *Candida* spp.—and favorably alter the qualitative and quantitative composition of the intestinal microbiota. It is indicated for individuals post-antibiotic therapy, those with fungal infections of the digestive tract (especially *Candida* overgrowth), and those with lactose or gluten intolerance. There is clinical testing associated with its effect on intestinal *Candida* overgrowth[1][3][6].

Brand names: Mycobiotic
Other names: Mycobiotic NSMycobiotic 100gMycobiotic100gMycobiotic-100g

Beyond the preview

Go deeper on mycobiotic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mycobiotic.

Explore the full profile